申请人:Huang Q. Charles
公开号:US20050049239A1
公开(公告)日:2005-03-03
The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.
该发明提供了新颖的GlyT2抑制化合物,可用于调节、治疗或预防:焦虑症;需要治疗受伤哺乳动物神经组织的状况;适合通过神经营养因子管理治疗的状况;神经系统紊乱;或肥胖症;与肥胖相关的疾病。